Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study

Background: Psoriasis is associated with a heightened risk of cardiovascular disease and higher prevalence of metabolic syndrome. Objective: Investigate the effect of metabolic syndrome and its factors on early coronary artery disease assessed as noncalcified coronary burden by coronary computed tomography angiography in psoriasis. Methods: This cross-sectional study consisted of 260 participants with psoriasis and coronary computed tomography angiography characterization. Metabolic syndrome was defined according to the harmonized International Diabetes Federation criteria. Results: Of the 260 participants, 80 had metabolic syndrome (31%). The metabolic syndrome group had a higher burden of cardiometabolic disease, systemic inflammation, noncalcified coronary burden, and high-risk coronary plaque. After adjusting for Framingham risk score, lipid-lowering therapy, and biologic use, metabolic syndrome (beta = .31; P < .001) and its individual factors of waist circumference (beta = .33; P < .001), triglyceride levels (beta = .17; P = .005), blood pressure (beta = .18; P = .005), and fasting glucose (beta = .17; P = .009) were significantly associated with noncalcified coronary burden. After adjusting for all other metabolic syndrome factors, blood pressure and waist circumference remained significantly associated with noncalcified coronary burden. Limitations: Observational nature with limited ability to control for confounders. Conclusions: In psoriasis, individuals with metabolic syndrome had more cardiovascular disease risk factors, systemic inflammation, and noncalcified coronary burden. Efforts to increase metabolic syndrome awareness in psoriasis should be undertaken to reduce the heightened cardiovascular disease risk.

Automated summary

The study revealed a significant association between metabolic syndrome and its factors with noncalcified coronary burden in patients with psoriasis. Individuals with metabolic syndrome had higher cardiovascular disease risk factors and systemic inflammation, highlighting the importance of increasing awareness and addressing metabolic syndrome in psoriasis patients to reduce cardiovascular risk.